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cost-effectiveness ratio (ICER) was €2059 in the base case,
varying from €1474 to €4963 according to the multi-ways sen-
sitivity analysis. CONCLUSIONS: The economic assessment
shows that TAC is cost-effective in the management of early
breast cancer in France with an ICER below the threshold com-
monly cited in such analyses.
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OBJECTIVES: CALGB conducted a randomized trial to
compare the survival duration, quality of life, and costs of
hepatic artery infusion (HAI) versus systemic chemotherapy
(SYS) as initial treatment for patients with colorectal cancer
metastatic to the liver. We evaluated the lifetime incremental cost
and beneﬁt from a third-party payer perspective alongside that
trial. METHODS: Resource use data were collected for all study
patients through 18 months, regardless of disease progression,
and a subset was followed until death. Unit costs were derived
from itemized patient bills, adjusted using department-speciﬁc
ratios of costs to charges. Utility weights were collected serially
from trial patients and used to calculate quality-adjusted sur-
vival. RESULTS: During the ﬁrst 18 months, inpatient stays
accounted for the highest proportion of overall costs (47%) in
the HAI arm, while outpatient visits were the major component
of costs (40%) in the SYS arm. In both arms, non-protocol
chemotherapy treatment given after progression accounted for
approximately half of all outpatient care costs. Compared to sys-
temic 5-ﬂuorouracil and leucovorin, hepatic artery infusion of
ﬂoxuridine increased quality-adjusted survival by 0.46 quality-
adjusted life years, at an incremental cost of $50,867. Most of
the difference in costs occurred early, and was attributable to
higher inpatient care and surgery costs. The incremental cost-
effectiveness ratio (ICER) was $112,924 per quality-adjusted life
year. The bootstrap-derived distribution of ICER was quite
precise, with only 28% and 90% of simulations falling under
$100,000/QALY and $200,000/QALY, respectively. The magni-
tude of the ICER was robust in sensitivity analyses. CONCLU-
SIONS: Hepatic artery infusion for metastatic colorectal cancer
resulted in a substantial increase in quality-adjusted survival at
an ICER that compares favorably with other widely used cancer
treatments in the United States. These results create a benchmark
against which the costs and cost-effectiveness of new agents can
and should be evaluated.
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OBJECTIVE: Anemia, a common complication of chemother-
apy, is often treated with erythropoiesis-stimulating proteins.
The objective of this study was to assess the cost-effectiveness of
once every three weeks (Q3W) 500mg Aranesp® (darbepoetin
alfa) administration compared to a weekly 150mg (QW) regimen
from a French societal perspective. METHOD: A decision-tree
model with a 16-week time horizon was developed in Excel®.
This model included the possibility to adapt darbepoetin alfa
dosing based on hemoglobin (Hb) criteria reported in guidelines.
The transition probabilities, the number of days with Hb ≥ 11
g/dL (effectiveness measure), and the units of blood transfused
were extracted from a randomized clinical trial. Unit costs were
applied to medical resources used (transfusions, darbepoetin
alfa, physician visits, hospitalizations, and administration time
by health care professionals) and patients’ time. Literature data,
validated by two French clinical experts, was used for inputs
regarding resource use. Time was valued at gross hourly wage
rate. Both time and medical costs were extracted from ofﬁcial
sources (AMELI; INSEE) and adjusted to 2005 values. A 5000-
replication probabilistic sensitivity analysis was performed with
@RISK® using distributions for both probabilities and time.
RESULTS: The effectiveness was similar between the two arms.
Switching patients from QW to Q3W resulted in a gain of 2.3
days with Hb ≥ 11g/dL (95% CI: -3.3; 7.6). Total costs were
slightly lower for Q3W (€4616 [95% CI: 4303; 4959]) compared
to QW (€4856 [95% CI: €4488; 5258]). Probabilistic sensitivity
analysis revealed 68% of replications with higher effectiveness
and lower costs for Q3W treatment (dominant); 11% with both
higher effectiveness and costs; 4% where Q3W was dominated
by QW and 17% showed both lower effectiveness and costs.
CONCLUSION: This analysis provides probabilistic informa-
tion to decision makers about the health economic impact of dar-
bepoetin alfa Q3W. A decision in favor of Q3W is more likely
to be beneﬁcial from a health economic viewpoint.
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OBJECTIVE: To estimate the cost-effectiveness of adjuvant
treatment with exemestane vs. tamoxifen for early-stage breast
cancer after 2–3 years treatment with tamoxifen, in Spain.
METHODS: A Markov state-transition model was performed
from the National Health System perspective, and simulates the
long-term outcomes over 10 and 20 years. The primary outcome
was the incremental cost-effectiveness of exemestane scheme in
terms of cost per quality-adjusted life year (QALY) gained. The
transition probabilities between health states (disease-free sur-
vival with or without complications, local recurrence, contralat-
eral breast cancer, systemic recurrence or dead) were derived
from the Intergroup Exemestane Study (IES) trial and from sec-
ondary Spanish sources. The costs associated with chemother-
apy and complications (bone fractures, vaginal bleeding, venous
thromboembolism, myocardial infarction) and unit costs
(€2005) were obtained from Spanish treatment guidelines and
Spanish health costs databases. A literature review was con-
ducted to derive the utility data. RESULTS: The average addi-
tional QALY per exemestane-treated patients were 0.200 and
0.557, for 10 and 20 years, respectively, compared with that of
tamoxifen alone scheme. The additional cost per QALY gained
obtained with exemestane was €70,990 and €39,170, respec-
tively. The sensitivity analyses conﬁrmed the robustness of the
base case analysis. CONCLUSIONS: According to this model,
adjuvant exemestane therapy after 2–3 years of tamoxifen
therapy signiﬁcantly improved disease-free survival as compared
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with the standard ﬁve years of tamoxifen treatment, with addi-
tional costs per QALY gained.
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OBJECTIVES: To identify cost consequences and cost effective-
ness of R-MCP (rituximab, mitoxantrone, chlorambucil, pred-
nisolone) vs. MCP from the perspective of a third party payer in
Germany (statutory sickness fund). METHODS: Resource uti-
lization data on 329 patients were collected in parallel to a RCT
and analyzed for the treatment phase (8 months). In addition,
an interim analysis of the subsequent observation period was
conducted. Data for initial chemotherapy, chemotherapy admin-
istration, treatment of adverse events, treatment of complica-
tions/progressive disease, subsequent chemotherapies, and
treatment for other reasons were collected. Several sensitivity
analyses were performed to address different cost environments
and discounting scenarios. RESULTS: Mean cost of the treat-
ment phase in the base case analysis was €35,600 for R-MCP
and €21,500 MCP per patient (p < 0.0001). More treatment
cycles were administered in the R-MCP arm (1026 MCP, 1237
R-MCP). Mean cost per patient and active treatment cycle was
€4900 for R-MCP and €3300 for MCP (p < 0.0002). Mean
observation period after end of initial treatment were 26.9
months for R-MCP and 25.8 months for MCP. Costs for treat-
ment of adverse events, new chemotherapies, treatment of pro-
gressive disease and other reasons was substantially reduced in
the R-MCP arm. This resulted in mean (undiscounted) cost per
patient in the observation period of €17,900 for R-MCP and
€30,700 for MCP (p < 0.01). Overall costs were €51,100 for R-
MCP and €53,900 for MCP (p = 0.6). Clinically, R-MCP resulted
in statistically signiﬁcant superior response rate, event free sur-
vival and overall survival. CONCLUSION: Initially higher treat-
ment costs of R-MCP were compensated by savings due to
reduced toxicity and better efﬁcacy after slightly more than two
years. Combined with the clinical superiority of R-MCP, this
regime is likely to prevail as the dominant treatment strategy
compared to MCP alone at the ﬁnal analysis (at four years 
observation).
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OBJECTIVES: Cetuximab in combination with irinotecan
(cet/iri) is a new chemotherapy option for patients with EGFR-
expressing metastatic colorectal cancer after failure of irinote-
can-including cytotoxic therapy. In Scotland, the prognosis for
patients with metastatic colorectal cancer (mCRC) is poor and
there are limited therapy options after the failure of conventional
cytotoxic agents. Our objective was to determine the incremen-
tal cost-effectiveness of cet/iri compared to current practice in
Scotland. METHODS: Given there are no licensed treatment
options for this patient group in Scotland, the economic evalua-
tion compared cet/iri with best/active supportive care (ASC). The
perspective of the economic evaluation was that of the National
Health Service in Scotland. The economic evaluation was based
on a pivotal clinical trial comparing cetuximab in combination
with irinotecan with cetuximab monotherapy (BOND). As the
BOND study did not directly compare cet/iri with ASC, the data
were ‘bridged’ to estimate overall survival. Sensitivity analyses
are presented by way of both probabilistic analysis and univari-
ate sensitivity analysis. RESULTS: Data from the BOND study
showed median time to disease progression (TTP) is signiﬁcantly
longer with cet/iri, 4.1 months, than cetuximab alone, 1.5
months. Median survival was 8.6 months for cet/iri and 6.9
months for cetuximab. In our evaluation, estimated mean overall
survival was 10.8 months for cet/iri and 5.6 months for ASC.
Over the duration of the economic model, cet/iri patients
incurred additional costs of £13,851 and gained additional 0.42
life-years per patient compared with ASC patients. The incre-
mental cost per life-year gained for cet/iri versus ASC was
£32,752. The incremental cost per QALY gained was £34,454.
CONCLUSIONS: Cet/iri is an effective chemotherapy option for
mCRC patients failing conventional cytotoxic agents and who
have limited therapy options. Our study shows that cet/iri is also
within the range of acceptable cost-effectiveness when compared
to other oncology therapies.
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OBJECTIVES: Although tamoxifen shows beneﬁt in the ﬁrst ﬁve
years of adjuvant therapy, extending its use by an additional ﬁve
years is not beneﬁcial. This has created an unmet medical need
for patients who are disease free after 5 years of standard adju-
vant therapy, but still have a signiﬁcant risk of relapse over the
following ten years. In a large randomized placebo-controlled
trial, letrozole signiﬁcantly reduced the risk of recurrence by
42% and the risk of distant metastases by 39%. The DFS was
signiﬁcantly improved with letrozole regardless of nodal status.
METHODS: A Markov model was developed to evaluate the
lifetime cost-utility of extended adjuvant letrozole in post-
menopausal women. The cost-utility analysis was based on the
results of the MA17 trial, from which patient-level data was used
to estimate event rates in both treatment groups. Expected costs,
life-years and QALYs were estimated by summing across all
health states and cycles for each treatment group. Deterministic
and probabilistic sensitivity analyses were performed to account
for uncertainty. RESULTS: The baseline results from the model
show ICERs of $30,100/LY and $34,058/QALY for a cohort of
1000 postmenopausal women. Letrozole is even more cost-effec-
tive in the node positive patient sub-group than for the aggre-
gate patient group, with an incremental cost per life-year of
$23,235 and an incremental cost per QALY of $26,553. For
node negative patients the model shows ICERs of $41,357 per
life-year and an incremental cost per QALY of $46,049. The sen-
sitivity analyses show narrow ranges for the credible intervals,
and for a threshold of $50,000/QALY the likelihood that letro-
zole would be cost-effective is 1.0 in node positive patients, while
being 0.77 in node negative patients. CONCLUSION: Our
model shows that letrozole is cost-effective in both node nega-
tive and node positive patients with ICERs far below the gener-
ally accepted threshold of $50,000/QALY.
